Lassogen is pioneering a new class of programmable medicines known as Lassotides™, which are engineered from lasso peptides—unique 3D molecular structures derived from bacterial sources. These lasso peptides exhibit remarkable stability against proteolytic, pH, and thermal degradation, making them advantageous for therapeutic applications. By harnessing the vast diversity of over 10,000 natural lasso peptides, Lassogen optimizes these molecules through amino acid variations at critical positions, enhancing their potency, selectivity, and safety. This innovative approach allows Lassotides™ to target challenging diseases that are inadequately addressed by traditional therapies, such as antibodies and small molecules.

The company's technology platform integrates advanced synthetic biology, computational modeling, and evolutionary techniques to discover and refine these lasso peptides. Lassogen employs a proprietary database of over 100,000 lasso peptide genes and utilizes cell-free biosynthesis for rapid production. Their focus on scaling up the manufacturing process involves using engineered organisms in fermentation systems, ensuring that the unique structures of lasso peptides can be synthesized effectively. With an initial emphasis on oncology, Lassogen is also exploring applications in autoimmune diseases, pain management, and inflammation, positioning Lassotides™ as a versatile therapeutic modality with significant potential in modern medicine.

United States

Lassogen is developing a new therapeutic modality based on lasso peptides that we are programming to treat difficult diseases such as cancer and autoimmune disorders. 

Lassogen

Company Details